Killing multiple myeloma cells with the small molecule 3-bromopyruvate: Implications for therapy
(2014) Anti-Cancer Drugs — Vol. 25, n° 6, p. 673-682 (2014)
Files
No attached file found for this publication.
Details
- Authors
- Abstract
- The small molecule 3-bromopyruvate (3-BP), which has emerged recently as the first member of a new class of potent anticancer agents, was tested for its capacity to kill multiple myeloma (MM) cancer cells. Human MM cells (RPMI 8226) begin to lose viability significantly within 8 h of incubation in the presence of 3-BP. The Km (0.3 mmol/l) for intracellular accumulation of 3-BP in MM cells is 24 times lower than that in control cells (7.2 mmol/l). Therefore, the uptake of 3-BP by MM cells is significantly higher than that by peripheral blood mononuclear cells. Further, the IC50 values for human MM cells and control peripheral blood mononuclear cells are 24 and 58 μmol/l, respectively. Therefore, specificity and selectivity of 3-BP toward MM cancer cells are evident on the basis of the above. In MM cells the transcription levels of the gene encoding the monocarboxylate transporter MCT1 is significantly amplified compared with control cells. The level of intracellular ATP in MM cells decreases by over 90% within 1 h after addition of 100 μmol/l 3-BP. The cytotoxicity of 3-BP, exemplified by a marked decrease in viability of MM cells, is potentiated by the inhibitor of glutathione synthesis buthionine sulfoximine. In addition, the lack of mutagenicity and its superior capacity relative to Glivec to kill MM cancer cells are presented in this study. © 2014 Wolters Kluwer Health Lippincott Williams & Wilkins.
Citations
Majkowska-Skrobek, G., Augustyniak, D., Lis, P., Bartkowiak, A., Gonchar, M., Ko, Y. H., Pedersen, P. L., Goffeau, A., & Ułaszewski, S. (2014). Killing multiple myeloma cells with the small molecule 3-bromopyruvate: Implications for therapy. Anti-Cancer Drugs, 25(6), 673-682. https://doi.org/10.1097/CAD.0000000000000094 (Original work published 2014)